Wilson Therapeutics announces support of the annual event

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Sep 21, 2016 at 2:15 AM

Wilson Therapeutics announces support of the annual event Big Wow to raise awareness of Wilson Disease

Wilson Therapeutics AB (publ) today announced its sponsorship of the second annual Big Walk on Wilson’s (Big Wow). The event will take place on October 1, 2016, in 24 cities across North America to increase awareness of Wilson Disease and raise funds for the Wilson Disease Association. “As the father of three sons, all diagnosed with Wilson Disease, I have personal experience with the importance of an early diagnosis,” said Christopher Simopoulos, MD, one of the initiators of the Big Wow. “We started the Big Wow last year to raise awareness of Wilson Disease among the public and the healthcare community. We were amazed by the success of this initiative, bringing together almost 1,400 walkers in 16 cities, and raising nearly $67,000. This is a great motivator to conduct further Big Wows, so that more patients are diagnosed earlier and we can reduce the well-known consequences of untreated Wilson Disease. We are extremely pleased that Wilson Therapeutics is supporting again this effort.” “We are impressed by the energy, drive and strong will of patients and caregivers affected by the debilitating consequences of Wilson Disease to improve the diagnosis and treatment of this rare disorder,” added Jonas Hansson, CEO of Wilson Therapeutics AB. “This community is actively looking for new treatment modalities that will rapidly relieve their symptoms, with fewer side effects and more convenient dosing”, he concluded. Wilson Therapeutics is sponsoring this important event as part of its commitment to improve the lives of patients with Wilson Disease. About Wilson Disease Wilson Disease is a rare genetic disease that causes serious copper poisoning. The genetic defect causes excessive copper accumulation, primarily in the liver and/or the central nervous system and the disease results in life-threatening damage to the liver and brain if left untreated. Wilson Disease affects approximately one in every 30,000 people worldwide, corresponding to a prevalence of approximately 10,000 patients in the US and 15,000 patients in the EU. About the Big Walk on Wilson’s Bringing together members of the Wilson Disease community, the Big Walk on Wilson’s (Big Wow), established in Sacramento, California, is a walk across America to raise funds for the Wilson Disease Association. This initiative took place for the first time on September 19, 2015. The second edition of this walk is scheduled October 1, 2016, in several cities across America. Funds from the Big Wow will help create a database of patients and enable sharing of information about treatment options. The public is invited to participate by walking in a city currently planning a walk, or by raising funds virtually online. Visit www.wilsonswalk.org for more information. About the Wilson Disease Association The Wilson Disease Association (WDA), based in Milwaukee, Wisconsin, is a volunteer organization striving to promote the well-being of patients with Wilson’s disease and their families and friends. WDA funds research, facilitate and promote the identification, education, treatment, and support of patients and other individuals affected by Wilson’s disease. Visit www.wilsonsdisease.org for more information. About Wilson Therapeutics Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, Decuprate®, is initially being developed as a novel treatment for Wilson Disease and is currently being evaluated in a Phase II clinical study. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. Visit www.wilsontherapeutics.com for more information. For further information contact: Jonas Hansson, CEO, Wilson Therapeutics AB Telephone: +46 8 796 00 00 Email: jonas.hansson@wilsontx.eu Wilson Therapeutics AB (publ) Org nr 556893-0357 Västra Trädgårdsgatan 15 SE-111 53 Stockholm

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Quanta Services Reports Record Q3 2026 Earnings

Quanta Services Smashes Q3 2026 Expectations If you're a stakeholder in Quanta Services, you'd probably be dancing in the aisles right now. This company just posted off-the-charts numbers for the third quarter of 2026. We're talking revenues of $12 billion—a staggering leap from $7.63 billion the same quarter last year. Explosive Earnings and Strong Backlog The star of...

Faith on Trial: La Luz del Mundo Faces Court Ruling

A Legal Battle Over Religious Freedom When folks start talking about religion intertwining with law, things get real tricky, real quick. The La Luz del Mundo church is knee-deep in such a legal tussle. On October 28, 2026, the United States District Court for the Southern District of New York gave a nod to the prosecution, denying the church's pretrial motions. What we've...

2026 Data Integration Stars: User Sentiments Revealed

Users Crown Data Integration Champions Right out of the gate, let's make one thing clear: when you're picking a data integration solution, you're essentially hitching your wagon to a vendor. This partnership, like any, can make or break your operations, and no one knows this better than the folks who've been through the trenches. Enter Infotech's 2026 Emotional Footprint...

Banco Macro S.A. Plans $160B Share Buyback Initiative

Tapping into Share Buybacks in a Tumultuous Market Out of nowhere, Banco Macro S.A. has decided to whip up a share buyback program, a lifeline for their current market value. Let me tell you, the market's more volatile than a caffeinated squirrel these days, hitting the financial scenery harder than a hammer on a glass table. So, Banco Macro's taken a deep breath and...

Smartpress: Adobe & Canva Shape Print Design World

Adobe's Stranglehold on Professional Design Over at Smartpress, they've pulled the curtain back on just how heavily Adobe Creative Suite weighs in on the print design sector. The company's recent analysis shines a light on the staggering 66% dominance of Adobe's InDesign and Illustrator in file submissions. That's a hefty portion influencing both the quality and financial...

Atlantic Blvd Apartments: A Game-Changer for Housing

A Bold Move for Attainable Housing Amidst the hustle and bustle of Sterling, Virginia, a new player has hit the scene: Atlantic Blvd Apartments. A property designed solely for attainable housing, this development is a showcase of what can be accomplished when local government and private developers team up with a shared vision. It feels like a breath of fresh air in a...

Data Breach at Lumara Bio: Privacy Lawsuits Loom

Another Day, Another Data Breach It seems like you can’t throw a stone without hitting a data breach these days—and this time, it’s Lumara Bio USA’s turn under the spotlight. The Princeton-based oncology therapeutics outfit, part of Germany’s ITM Isotope Technologies, spilled some beans it never meant to. We're talking some pretty sensitive stuff here, folks....

Clip Expands Horizons with Pulpos Acquisition, New Board Member

Clip's Strategic Move with Pulpos Clip just laid down a serious marker in the digital payment world by snagging Pulpos, a firm that’s got its claws deep into AI-driven business management software. This move isn't just some fancy headline. It's a real, grounded step in expanding Clip's ecosystem to bolster the backbone of Mexico's economy: small and medium-sized...

Infection Control Market Set for Explosive Growth by 2031

Untangling the Surge in Infection Control Demand Lately, it's like every healthcare joint worldwide is scrambling for better infection control. We're talking about a market poised to jump from a whopping USD 58.5 billion in 2026 to USD 80.2 billion by 2031—a tidy 37% uptick. That change, brewing at a 6.5% CAGR, speaks volumes about where the industry's heading. What's...

Genefluence Launches Rapid UTI PCR Test at Chelsea Hospital

There's a fresh breeze blowing through the dusty corridors of healthcare, shaking things up for the better. You see, Genefluence, the brainchild of Professor Chris Toumazou, isn't just throwing a bunch of tech jargon around—it's setting the stage for a much-needed shake-up in how we handle urinary tract infections (UTIs) and, believe me, it couldn’t have come sooner....